Abstract. Autosomal recessive polycystic kidney disease (ARPKD; MIM 263200) is a hereditary and severe form of polycystic disease affecting the kidneys and biliary tract with an estimated incidence of 1 in 20,000 live births. The clinical spectrum is widely variable: up to 50% of affected neonates die shortly after birth, whereas others survive to adulthood. Mutations at a single locus, polycystic kidney and hepatic disease 1 (PKHD1), are responsible for all typical forms of ARPKD. Mutation detection was performed in PKHD1 by DHPLC in 85 affected, unrelated individuals. Seventy-four amplicons were amplified and analyzed from the PKHD1 genomic locus. Sequence variants were considered pathogenic when they were not observed in 160 control individuals (320 chromosomes).
Abstract. Autosomal recessive polycystic kidney disease (ARPKD; MIM 263200) is a hereditary and severe form of polycystic disease affecting the kidneys and biliary tract with an estimated incidence of 1 in 20,000 live births. The clinical spectrum is widely variable: up to 50% of affected neonates die shortly after birth, whereas others survive to adulthood. Mutations at a single locus, polycystic kidney and hepatic disease 1 (PKHD1), are responsible for all typical forms of ARPKD. Mutation detection was performed in PKHD1 by DHPLC in 85 affected, unrelated individuals. Seventy-four amplicons were amplified and analyzed from the PKHD1 genomic locus. Sequence variants were considered pathogenic when they were not observed in 160 control individuals (320 chromosomes). For purposes of genotype-phenotype comparisons, families were stratified by clinical presentation into two groups: the severe perinatal group, in which at least one affected child presented with perinatal disease and neonatal demise, and the less severe, nonperinatal group, in which none of the affected children died in the neonatal period. Forty-one mutations were found in 55 affected disease chromosomes; 32 of these mutations have not been reported previously. Mutations were distributed throughout the portions of gene encoding the predicted extracellular portion of the protein product. The most commonly encountered mutation, T36M, was found in 8 of 55 disease chromosomes. Amino acid substitutions were found to be more commonly associated with a nonlethal presentation, whereas chain terminating mutations were more commonly associated with neonatal demise ( 2 ϭ 11.54, P ϭ 0.003). All patients who survive the neonatal period have at least one amino acid substitution mutation, suggesting that such substitutions produce milder disease through production of partially functional protein products. The nature of the germline mutations in ARPKD plays a significant role in determining clinical outcome.
Autosomal recessive polycystic kidney disease (ARPKD; MIM 263200) is a hereditary and severe form of polycystic disease affecting the kidneys and biliary tract with an estimated incidence of 1 in 20,000 live births (1) . The clinical spectrum is widely variable: up to 50% of affected neonates die shortly after birth, whereas others survive to adulthood (2, 3) . Mutations at a single locus, polycystic kidney and hepatic disease 1 (PKHD1), are responsible for all typical forms of ARPKD (4, 5) . It has been proposed that the relative concordance of phenotypes within the majority of families and the wide variation between families (6) are the result of allelic heterogeneity at the PKHD1 locus (1, 7) . The discordance of phenotypes within a minority of sibships (8, 9) may represent the additional modifying effects of other genetic loci and environmental factors (2) .
The clinical spectrum of ARPKD is widely variable, with most cases presenting in infancy. Children with early and severe presentations typically exhibit markedly enlarged echogenic kidneys and oligohydramnios in association with intrauterine renal failure. As a result of the oligohydramnios, approximately 50% of affected neonates have the Potter sequence, with pulmonary hypoplasia, a characteristic facies, and deformities of the spine and limbs. At birth, these neonates often have a critical degree of pulmonary hypoplasia and die within the first few hours of life as a result of respiratory insufficiency. In affected neonates, the kidneys are symmetrically enlarged and cysts appear as fusiform dilations of col-lecting ducts extending radially from the renal pelvis to the cortex (2) . The ectatic collecting ducts are lined by cuboidal epithelia that retain lectin-binding properties of the segments of origin (10) . In less severely affected children, the extent and degree of collecting duct dilation is more limited and the course is more chronic with accompanying loss of glomeruli, tubular atrophy, and interstitial fibrosis (2) . A minority of affected individuals survive well into adulthood (3). The principal causes of morbidity and mortality in affected children are hypertension, progressive renal insufficiency, and portal tract fibrosis (2) . Hypertension, which can be severe, occurs in 75 to 100% of patients and can occur in the setting of preserved renal function. Among children who survive the immediate perinatal period, approximately 50% progress to ESRD in the first decade (11) . Congenital hepatic fibrosis results from ductal plate malformation that leads to biliary dysgenesis (12) . Portal tract fibrosis and portal hypertension are the significant clinical sequelae. There is substantial variation in the relative severity of presentation of the renal and hepatic components of the ARPKD phenotype (2, 8) . However, all patients have histopathologic presence of congenital hepatic fibrosis, and some physicians require this finding to make a diagnosis of ARPKD.
PKHD1 was recently discovered as a novel gene that extends over approximately 500 kb on chromosome 6p12 and is strongly expressed in fetal and adult kidney, with weaker expression in liver and other tissues (13, 14) . The longest transcript contains 67 exons with an open reading frame composed of 66 exons encoding a 4074 -amino acid protein, polyductin/ fibrocystin (13, 14) . It is predicted to have a single transmembrane-spanning domain very near its carboxyl terminus and multiple IPT/TIG domains and PbH1 repeats in its predicted approximately 3860 -amino acid extracellular NH 2 -terminus (13, 14) . ARPKD results from partial or complete loss of polyductin/fibrocystin function (13, 14) . The structure and domain composition of the deduced protein combined with knowledge of the human disease phenotype suggests that polyductin/ fibrocystin is a cell-signaling molecule (receptor, co-receptor, or ligand) that is essential for maintaining normal development and function of renal tubules and bile ducts. The presence of the PbH1 domains shared with proteins of the pectin lyase superfamily suggests that polyductin/fibrocystin may have catalytic activity on polysaccharide substrates.
The advent of the discovery of PKHD1 has permitted the definition of causative mutations in affected families and the potential for correlation of these mutations with the diverse spectrum of interfamilial clinical variation. In the current study of an ethnically diverse population, we describe 41 mutations in 55 affected disease chromosomes; 32 of these mutations have not been reported previously (13) (14) (15) . Mutations were distributed throughout the region of gene encoding the predicted extracellular portion of the protein product. We found that amino acid substitutions were more commonly associated with a nonlethal presentation, whereas chain-terminating mutations were more commonly associated with neonatal demise. All patients who survived the neonatal period had at least one amino acid substitution mutation, suggesting that some amino acid substitution mutations produce milder disease and may be associated with a better prognosis.
Materials and Methods

Patients and Samples
Families and individuals were ascertained from databases at the University of Alabama at Birmingham and the Rheinishch-Westfalische Technishce Hoechschule (Aachen, Germany). ARPKD was diagnosed according to the criteria of Zerres et al. (1) . Study subjects and family members provided informed consent by approved protocols at the recruiting institutions. Study subjects represented the full spectrum of clinical presentations for ARPKD (Table 1) . Genomic DNA was prepared from whole blood by standard protocols (13) .
Mutation Detection
We PCR-amplified 74 amplicons from the PKHD1 genomic locus using a set of primers designed to amplify exon sequences, the adjacent splice sites, and approximately 40 nucleotides of flanking sequence on each side (15) . Several primers were modified for the current study (Table 2 ). Amplified fragment sizes ranged from 149 to 587 nucleotide bases. Exons 32, 59, and 65 were amplified in 4, 3, and 3 overlapping PCR products, respectively, to limit the size of the amplicons. PCR product sequences were optimized for DHPLC by selection of primer pairs that minimized the temperature difference in melting domains across the region as determined by the Wavemaker version 4.1 system control software (Transgenomic, Inc., Omaha, NE). Amplifications were performed using 96-well plates in a Perkin Elmer 9700 thermal cycler with the following conditions: initial denaturation at 94°C for 4 min followed by 35 cycles of 30 s each at 94°C, at the amplicon-specific annealing temperature (Table 2 ) (15) , and at 72°C, followed by a final extension at 72°C for 7 min. Standard PCR reactions were prepared in 30 l using 20 ng of genomic DNA and 0.5 unit of either regular Taq or AmpliTaq DNA polymerase (PE Biosystems, Foster City, CA). The reaction volume provided amplification product for two rounds of DHPLC analysis as well as for sequencing templates.
Mutation detection was performed by heteroduplex analysis using the Transgenomic Wave DHPLC system (Transgenomic, Inc.). PCR products were denatured at 98°C for 4 min and allowed to reanneal in the thermocycler block for 30 min. Samples were placed into the DHPLC autosampler and held at 10°C as 8 to 12 l of each amplicon was injected onto the column. The mobile phase consisted of a mixture of Buffers A (0.1 M TEAA and 1 mM EDTA) and B (25% acetonitrile in 0.1 M TEAA). The buffer gradient and optimum denaturing temperature required for successful resolution of heteroduplexes for each amplicon were determined according to the Wavemaker version 4.1 system control software. Samples were eluted with a linear acetonitrile gradient at a flow rate of 0.9 ml/min over 7 min and routinely analyzed at two denaturing temperatures. Samples showing altered elution properties not present in controls were purified (Qiaex; Qiagen, Inc., Valencia, CA) and sequenced in both directions with BigDye Deoxy Terminator cycle sequencing on an ABI 3700 DNA sequencer (Applied Biosystems, Foster City, CA). The PCR primers were also used for sequencing reactions. Sequence variations were identified by visual inspection and comparison of the resulting electropherograms (Editview, version 1.1; Applied Biosystems). When amplicons had altered elution properties in both control and patient DNA, both samples were sequenced to confirm their identity at the nucleotide level. All putative mutations were tested by segregation analysis when family material was available. Table 1 . Among patients with perinatal presentation and neonatal demise, all have nephromegaly and most had rapid and severe course during which systemic hypertension may not have established itself; hence, absence of Sys HTN in this group needs to be interpreted in light of the clinical course.
e Mutations described for the first time in the current report.
Statistical Analyses
Genotype-phenotype comparisons were performed using 2 analysis with continuity correction; Fisher exact tests were computed when sample size was small. In our primary analysis, we compared allelic and genotypic frequencies of chain-terminating and amino acid substitution mutations among our patients (current report and (13)) with and without perinatal presentation. We extended this analysis to include patients reported in the literature (14, 15) . With four primary evaluations, P Ͻ 0.0125 was considered significant after Bonferroni correction for multiple comparisons. Statistical analyses were performed using SPSS 11.0.
Results
Mutation Detection in PKHD1
DHPLC is well suited for discovery of heterozygous mutations but may be less robust for detection of homozygous mutations in the absence of mixing strategies. However, because most ARPKD patients seem to be compound heterozygotes in the absence of known consanguinity or founder mutations (13-15), we expected DHPLC to be a good mutation detection modality for this study even without mixing studies. We performed mutation detection in PKHD1 by DHPLC in 85 affected, unrelated individuals. Among these, 60 samples underwent complete screening of the 67 exons that compose the transcript with the longest predicted ORF of PKHD1. Another 25 individual samples underwent partial screening of an average of 42 exons of the gene as a result of insufficient genomic DNA template to complete the screen. In total, we identified 49 pathogenic sequence variants affecting 75 disease chromosomes (current study and (13)). The criteria for calling a sequence variant a mutation included a predicted chain-termination effect on the translation product, segregation with the disease phenotype, and absence of the variant in 160 control individuals (320 chromosomes). Among the 60 samples that were screened completely, mutations were found on both chromosomes in 22 individuals (37%), mutation on one chromosome was found in 18 samples (30%), and no mutations were found in 20 samples (33%). Overall, when the entire gene was screened, mutations were found in 62 of 120 disease chromosomes, approximately 52% detection efficiency. Eight of the patients in whom both mutations were found and four with one mutation have been reported previously (13) . Not surprising, when less than the entire gene was screened, the detection was less efficient: 13 (52%) with one mutation found and 12 (48%) with no mutations found.
We found 41 different mutations in 55 disease chromosomes to go along with the 20 mutations from the same study that we reported previously (Table 1 ; Figure 1 (13) ). Among the 55 disease chromosomes, 36 chromosomes contained 32 novel mutations that have not been described previously (13) (14) (15) . Our study population was ethnically diverse (Table 1 and (13)). We did not find evidence for founder mutations in this population, with the possible exception of the previously reported R1624W amino acid substitution seen in Saudi Arabian patients (13) . Several mutations were identified in multiple unrelated individuals (Figure 1 ). Most notable, the previously described T36M variant stood out as a particularly common mutation in our population. It occurred in 8 of the 55 disease chromosomes described in this report and in 9 of the 75 chromosomes when we combined it with our previous report (13) . T36M was found in seemingly unrelated individuals across national boundaries and has been described in each study reporting PKHD1 mutations to date (13) (14) (15) . Others have suggested that it has recurred de novo a number of times (15) and may represent a mutational "hot spot." We cannot rule out a founder effect for T36M as it seems to be particularly highly represented in German and central European populations in both this study and previous reports (15) . Given the potential limitation of DHPLC in detecting homozygous variants and the finding that 10 to 15% of our heterozygous mutant chromosomes had T36M, we considered the possibility that some patients in whom no mutations were found were in fact homozygous for T36M. We excluded homozygous T36M mutations by direct sequencing in the 32 samples in which no mutations were discovered.
Mutations are distributed throughout the gene but confined to the predicted extracellular portion of the predicted protein.
There is a preponderance of amino acid substitution changes. We found 46 (61%) amino acid substitution changes and 29 (39%) predicted chain-terminating mutations among mutations detected in 75 disease chromosomes. All amino acid substitutions described as mutations were absent in 320 control chromosomes. Of the 32 different amino acid substitutions that we found (Figure 1 ), all but three (R760, R1624, and I3177) occurred in residues conserved in the mouse protein (16) . The predominance of amino acid substitution mutations is not an artifact of detection because heteroduplex analysis should be most efficient in picking up insertion/deletion mutations resulting in frame shifts and should be equally effective in detecting single nucleotide substitutions regardless of whether they result in amino acid substitutions, nonsense codons, or splice site variants. Because we found mutations distributed roughly evenly along the gene, it is less likely that regional differences in our mutation detection sensitivity lead to underdetection of chain-terminating variants. Furthermore, two other published reports (14, 15) found a total of 74 (57%) amino acid substitutions and 55 (43%) chain-terminating mutations on 129 disease chromosomes. Combining all studies, mutations on 204 disease chromosomes were composed of 120 (59%) amino acid substitutions and 84 (41%) putative chain terminations. When the recurrent and overrepresented T36M mutation (38 of 204 disease chromosomes) and the Finnish founder mutation R496X (20 of 204 disease chromosomes (15)) are removed from the calculations, the reports still describe 82 (56%) disease chromosomes with missense changes and 64 (44%) with chain terminations (13-15).
Polymorphism in PKHD1
As part of mutation detection, we defined a spectrum of polymorphisms in PKHD1 (Table 3) . Because the majority of mutations in PKHD1 are private amino acid substitutions, it is important to develop a catalog of polymorphisms to assist in evaluating gene-based mutation results. We found 14 amino acid substitution polymorphisms that were present in the normal control population. As expected, in contrast to the missense mutations that overwhelmingly occurred in conserved residues (29 of 32; 91% in our study), 7 of 14 (50%) missense polymorphisms occurred in amino acids not conserved in the mouse protein (Table 3 ). An amino acid substitution previously reported as a mutation (D3139Y) was found to be a polymorphism when an expanded number of normal chromosomes was screened (Table 3) (13, 14) . The additional intragenic polymorphisms that we found can be used in future haplotype analyses. In the current studies, we did not have access to family members' DNA for the majority of patients and therefore were not able to determine haplotypes for mutant chromosomes.
Genotype-Phenotype Correlations
We sought to determine whether the nature of the underlying mutations played a role in disease severity in ARPKD. We stratified families by clinical presentation into two groups: the severe perinatal group, in which at least one affected child presented with perinatal disease and neonatal demise, and the less severe, nonperinatal group, in which none of the affected children died in the neonatal period. We dichotomized mutations into amino acid substitution and chain-terminating groups-the latter included nonsense, insertion/deletion with frame shifting, and putative splice site variants-on the premise that chain-terminating mutations were likely to be complete loss of function variants, whereas amino acid substitutions may be an admixture of hypomorphic alleles of varying degrees of functional loss (Figure 1) . Among families in which at least one mutation was found, 27 families had the severe perinatal presentation and 22 families had nonperinatal presentation. In four families (AL24, AL25, and AL34 in Table 1 and 306/1272 in Onuchic et al. (13)), we did not have enough clinical information, usually because of prenatal diagnosis and termination, for inclusion in the analysis. Among the 75 disease chromosomes from the 53 families for which we identified the mutations, 37 were from families with the severe perinatal form, 32 were from families with the nonperinatal disease, and 6 were from families with unknown disease severity (Table 4) . We found that amino acid substitution mutations were more commonly associated with the nonperinatal phenotypes, whereas chain-terminating mutations were more commonly associated with the perinatal severe phenotype ( 2 ϭ 7.89, P ϭ 0.005; Table 4 ). When we combine our study with published studies by Bergmann et al. (15) and Ward et al. (14) , the association of amino acid substitutions with nonperinatal presentation and of chain-termination mutations with perinatal presentations in 197 disease chromosomes remains highly significant ( 2 ϭ 19.65, P ϭ 9.4 ϫ 10 Ϫ6 ; Table 4 ). Excluding both T36M and R496X to eliminate potential bias introduced by overrepresented mutations does not alter this significant association among the remaining 140 disease chromosomes ( 2 ϭ 11.24, P ϭ 8.1 ϫ 10 Ϫ4 ). We further examined these data by evaluating genotype and phenotype in 20 patients in whom we found the mutations on both disease chromosomes. We found a trend toward association of amino acid substitutions with milder presentations and chain terminations with more severe presentation ( 2 ϭ 3.96, P ϭ 0.047; Fisher exact P ϭ 0.091). When we combined these data with the studies of Bergmann et al. (15) and Ward et al. (14) , the association of mutations with severity of phenotype in individuals in whom both mutations were known was confirmed (n ϭ 68 patients; 136 chromosomes; 2 ϭ 9.08, P ϭ 0.0026; Table 4 ). Finally, we examined the correlations of phenotype in patients with two amino acid substitution mutations, two chainterminating mutations, or one of each (Table 4) . When we combined our 20 patients with both mutations known with those of Bergmann et al. (15) and Ward et al. (14) (n ϭ 68), we found that all patients who survived the perinatal period (n ϭ 24) had at least one amino acid substitution. Conversely, all patients with two predicted chain-termination mutations (n ϭ 16) had perinatal presentation with neonatal death. Thus, the presence of a single amino acid substitution is required for presentation of a nonperinatal phenotype ( 2 ϭ 11.54, P ϭ 0.003). Having either one or two amino acid substitution mutations did not preclude a severe perinatal phenotype, although the trend was toward a milder presentation. The data are consistent with the notion that the nature of the germline mutations in ARPKD play a role in determining the phenotype and that amino acid substitution mutations can be less severe than mutations that lead to chain termination. a All mutations in the current study and (13) where the clinical phenotype was known; 2 ϭ 7.89, P ϭ 0.005. b All mutations in the current study and (13) (14) (15) where the clinical phenotype was known; 2 ϭ 19.65, P ϭ 9 ϫ 10 Ϫ6 . c All mutations in the current study and (13) (14) (15) where both mutations in an individual as well as the clinical phenotype was known; 2 ϭ 9.08, P ϭ 0.0026. d All mutations in the current study and (13-15) where both mutations in an individual as well as the clinical phenotype was known; 2 ϭ 11.54, P ϭ 0.003.
Discussion
An expected benefit from human disease gene identification is the ability to understand the molecular basis of clinical variation in disease presentation and outcome. Such correlation of the underlying molecular defect with the clinical course can improve both the care provided to patients and the understanding of the molecular pathogenesis of the disease. Historically, ARPKD has been subdivided clinically into four distinct phenotypes on the basis of the age at presentation and the proportion of dilated collecting ducts (6) . The degree of hepatic fibrosis has been noted to be inversely correlated to both the age at presentation and the degree of cystic involvement of the kidneys, but significant variation in this relationship has been described (7, 8) . There is relative concordance in the clinical presentation of ARPKD among siblings in most cases (17, 18) . There are, however, numerous instances of siblings that are discordant across the spectrum of renal and biliary tract involvement (17, 19) . Nonetheless, it is likely that allelic variation plays a significant role in the interfamilial variation that is well described for the disease presentation (8, 7, 20) . Such allelism is likely further modified by either additional genetic or environmental factors that account for intrafamilial variation and contribute to the interfamilial variation in the setting of comparable genotypes.
We examined the contribution of germline mutations to the ARPKD phenotype. We used a binary assessment of clinical presentation based on whether the affected children survived the immediate perinatal period. This end point was chosen because it was reliably available for almost all of our patient sample and could be gleaned from the recently published literature reporting additional mutations in ARPKD. In addition, numerous studies have suggested that the stratified classification of Blyth and Ockenden (6) has limited clinical utility and is not genetically relevant (reviewed in (2)). The hypothesis that we sought to test was whether at least part of the difference in the severity of clinical presentation between families results from the nature of the germline mutations. We found that in our patient sample and in those published with known mutations, survival past the immediate perinatal period required the presence of at least one amino acid substitution mutation; the presence of two chain-terminating mutations invariably resulted in perinatal lethality. However, the converse did not apply: the presence of an apparent missense variant did not guarantee escape from neonatal lethality. One interpretation of the finding of presence of missense mutations is required for but not necessarily sufficient for escape from neonatal lethality is that some amino acid substitutions act as hypomorphic alleles with reduced function, whereas others result in complete loss of function similar to chain-terminating mutations. Phenotypic variation in the effects of the hypomorphic amino acid substitutions are further determined by genetic or environmental modifiers; such modification of complete loss of function alleles is less likely.
Because most mutations recur infrequently, it so far has not been possible to get sufficient numbers of specific variants in unrelated patients to draw significant conclusions regarding direct correlation of individual mutations with severity. Inspection of the majority of recurrent missense variants did not allow conclusion that particular amino acid substitutions were exclusively associated with perinatal survival. Some recurrent mutations (e.g., I222V, I2331K, R1624W, Y2863G) were more often found in milder presentations, but the number of chromosomes for each was small. The T36M variant is unique in this regard because it is recurrent and seems to have arisen de novo several times. Among 68 patients with two known mutations, T36M was found on 12 chromosomes in 11 patients. Among these 11 patients, 6 had T36M in conjunction with another amino acid substitution and 1 was homozygous for T36M (15) . Only 2 of 11 patients, with T36M in association with I222V and V3471G, had the less severe presentation. The remainder had the severe perinatal presentation, including all four patients with T36M in conjunction with chain-terminating mutations and the one patient homozygous for T36M. It is interesting that the T36M amino acid substitution represents a potential alternative initiation codon that is actually predicted to be stronger than the native start codon when analyzed by the NetStart program (www.cbs.dtu.dk/services/NetStart). If the alternative start site were used exclusively in vivo, then the translation product would lack the leader sequence required for proper folding and T36M may indeed behave like a complete loss of function allele akin to the chain-terminating mutations. The clinical findings reported to date are consistent with this hypothesis, but additional studies, including functional assessment of T36M, are required for verification.
It is possible that the location of amino acid substitutions along the polyductin/fibrocystin protein may influence the severity of the resultant phenotype. Our detection of nucleotide substitutions was fairly homogeneous across the gene ( Figure  1) , and the analysis of Bergmann et al. (15) also seemed well distributed across the gene. Among the 68 patients with two known mutations, there were 39 different amino acid substitution mutations accounting for 75 of 136 disease chromosomes. Of the 39 different missense changes, 17 occurred exclusively on chromosomes in nonneonatal lethal cases, whereas 22 occurred on chromosomes associated with severe perinatal cases; some of the latter were also found in nonneonatal lethal presentations. The distribution of amino acid substitutions found exclusively in less severely affected individuals was 3, 9, 3, and 2 in successive 1000 amino acids quartiles of the 4074 amino acid protein. The distribution of missense variants associated with neonatal lethality was 8, 5, 5, and 4 in the respective quartiles. More than 50% (9 of 17) of amino acid substitutions in milder presentations occurred between residues 1000 and 2000; of these, 6 (35%) of 17 occurred in 10% of the sequence between amino acids 1600 and 2000. Thus, one third of missense variants exclusively associated with milder presentation occurred in a region of the protein between the clusters of IPT domains and PbH1 repeats that is devoid of identifiable structural motifs (Figure 1 ). Further studies with larger numbers of mutations defined in clinically well-characterized patient populations will better define the significance, if any, of the location or the type of amino acid substitution mutations with respect to disease prognosis.
Using the disease severity stratification criteria that we chose, we were unable to see a trend toward better outcomes with two, as opposed to one, amino acid substitution mutations. There are several potential explanations for this. The first is that we used a binary outcome measure (neonatal survival versus no survival), and it is possible that to see the mutation "dosage" effect of having one or two missense variants, a more continuous outcome measure (e.g., length of survival to kidney failure or liver transplantation) may be required. Another possibility is that a significant proportion (e.g., Ͼ50%) of amino acid substitution mutations are pathophysiologically equivalent to chain-termination mutations. Under these circumstances, a much larger group of patients with two known mutations may be needed to see the dosage effect. The third consideration is the effect of modifying factors. In light of the several reports of marked intrafamilial variation in ARPKD (17, 19) and our observations that certain mutations can be associated with severe as well as less severe outcomes, it is likely that geneby-gene and gene-by-environment interactions play an additive role in outcomes of patients. The uniformly severe outcome when patients have two chain-terminating mutations support the hypothesis that modifiers will likely have their greatest effect in the setting of one or two amino acid substitution mutations that have some degree of residual function that allow for a less severe presentation.
Finally, it has been noted that the primary cause of neonatal lethality in ARPKD is pulmonary hypoplasia in the setting of massive enlargement of the kidneys and intrauterine renal failure with consequent oligohydramnios (reviewed in (2,21) ). One way to reconcile these clinical observations with the finding that apparent complete loss of function mutations are associated with the severe presentation is to hypothesize that the kidney phenotype varies with the "molecular severity" of the mutation and in turn brings about early death through pulmonary failure. If the molecular lesion is milder, then both kidney and liver diseases run their relative courses, leading to the variable prognosis of children's surviving the neonatal period. There is precedent for the kidney tubules being developmentally more sensitive to polycystic disease mutations than the bile duct. Homozygous inactivation of either Pkd1 or Pkd2, the dominant polycystic kidney disease orthologs, results in severe intrauterine renal cystic disease with normal-appearing livers (22, 23) . However, when embryonic lethality is circumvented, surviving mice develop bile duct-derived cysts in addition to massive kidney cysts in postnatal life (S. Somlo, unpublished observations). Thus, it may be that early in development, the kidney is most sensitive to loss of PKHD1. Manifestation of the severe clinical liver lesion requires survival to a later stage. An extreme example of this is the two patients in our study (AL31 and AL33) who had portal hypertension but no discernible kidney disease from either clinical or radiologic perspectives. The known mutation in each of these patients was a unique amino acid substitution (Table 1) . Understanding the genetic factors underlying the clinical course of ARPKD will likely be the first step in tailoring clinical management of ARPKD to individual families' needs.
